Novel Cancer Therapy Had High Response Rates
A phase 1 study found that patients naive to prior T-cell therapy showed significant responses to the new drug, ramantamig.
Updated on Sept. 28, 2026 in Cancer
Live Poll
Should cancer patients have more access to advanced immunotherapies in outpatient settings?
In a phase 1 study, the drug ramantamig achieved an overall response rate of 93.6% among patients naive to prior T-cell-redirecting therapies. These early results offer a potential new avenue for cancer treatment as the therapy moves toward broader clinical evaluation.
Why it matters
This development represents a potential shift in how clinicians manage advanced blood cancers by targeting multiple receptors simultaneously. The study also explores new outpatient administration protocols, which may change future standards for patient care and treatment access.
A phase 1 study of 56 treated patients reported a 93.6% overall response rate and 76.6% complete response rate or better. Among evaluable patients, 100% achieved MRD-negativity, with an 84.6% progression-free survival rate recorded at 18 months.
The players
Colorado Blood Cancer Institute
A clinical research center specializing in the investigation of novel therapies for hematologic malignancies.
Sarah Cannon Research Institute
A global oncology research organization that leads phase 1 and advanced clinical trials for new cancer drug development.
The details
Ramantamig works by simultaneously engaging three targets: BCMA, GPRC5D, and CD3. Researchers also successfully utilized prophylactic tocilizumab in an outpatient cohort of 30 patients to mitigate side effects. This approach effectively reduced cytokine release syndrome rates to 30%, with no instances of ICANS or GPRC5D-associated cerebellar toxicity observed in that group.
Timeline
2026: Phase 1 study results presented at IMS 2026.
Health Landscape
This study advances the current efforts of the Sarah Cannon Research Institute phase 1 oncology research program by demonstrating the safety of outpatient dosing for complex multi-target therapies. It marks a significant progression in the development of T-cell-redirecting agents beyond traditional single-target approaches.
Patients and families interested in these findings should consult with an oncologist to determine if clinical trials are an appropriate consideration for their specific diagnosis. Given the preliminary nature of phase 1 data, discussions with a physician are essential for understanding risks and current treatment options.
The takeaway
Ramantamig shows high response rates in early testing, particularly for patients who have not previously received T-cell-redirecting therapies. Those managing blood cancer should track future updates on this drug's clinical progress and discuss its potential relevance with their care team.
Further reading
For more on advancements in hematology, visit the Cancer section.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Should cancer patients have more access to advanced immunotherapies in outpatient settings?
